QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Anderson, D. C Search for Related Content PubMed PubMed Citation Articles by Anderson, D. C, Jr

DIABETES

Pharmacologic Prevention or Delay of Type 2 Diabetes Mellitus

Clinical Associate Professor, Southwest Georgia Pharmacy Program, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA; Albany State University, 504 College Dr., ACAD-161, Albany, GA 31705-2796, fax 229-430-3223, danderso{at}mail.rx.uga.edu

Reprints: Dr. Anderson

OBJECTIVE: To evaluate the current data on pharmacologic interventions intended to prevent or delay the onset of type 2 diabetes mellitus.

DATA SOURCES: Searches of MEDLINE (1966-July 2002) and an extensive manual review of journals were performed using the key search terms diabetes mellitus, metformin, acarbose, troglitazone, orlistat, nateglinide, risk reduction, and prevention.

STUDY SELECTION AND DATA EXTRACTION: All articles identified from the data sources were evaluated, and all information deemed relevant was included for this review. Randomized controlled trials and meta-analyses were included if the primary outcome measure was prevention of diabetes and/or change in the rate of progression to diabetes.

DATA SYNTHESIS: Type 2 diabetes mellitus is a growing epidemic. Major risk factors include obesity, impaired glucose tolerance, and impaired fasting glucose. Complications of diabetes result in significant morbidity and mortality and are a substantial public health issue. Four randomized, blinded, controlled trials have assessed the efficacy of different medications, including metformin, troglitazone, acarbose, and orlistat, at decreasing the risk of progression to diabetes in patients at risk for developing diabetes. All of these agents decreased the risk of progression to diabetes.

CONCLUSIONS: Metformin, troglitazone, acarbose, and orlistat have been shown to decrease the risk of progression to diabetes in patients at risk for developing diabetes. Other questions that address issues such as identifying target populations, cost-effectiveness, and screening strategies must be answered to more fully define the place of pharmacologic therapy to prevent or delay diabetes.

Key Words: acarbose, diabetes mellitus, metformin, nateglinide, orlistat, risk reduction, troglitazone

Published Online, November 23, 2004. www.theannals.com, DOI 10.1345/aph.1E081

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-005-H01

This article has been cited by other articles:

				C. L Gillies, K. R Abrams, P. C Lambert, N. J Cooper, A. J Sutton, R. T Hsu, and K. Khunti Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis BMJ, February 10, 2007; 334(7588): 299 - 299. [Abstract] [Full Text] [PDF]